Company Description
Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer.
The company’s products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer and other solid tumors with MET dysregulation; and APL-102, an oral active, small molecule multiple tyrosine kinase inhibitor, which is in a in a Phase 1 clinical trial for cancer treatment.
It also develops immuno-oncology products, such as APL-501, an anti-PD-1 antibody product candidate, which is in phase 1 clinical trial for the treatment of advanced or relapsed/refractory solid tumors; APL-502, an anti-PD-L1 antibody product candidate for the treatment of tumors; APL-810, a novel, rationally designed, ACCI recombinant vaccine for the treatment of gastrin immunogen; and APL-801, a CD40 and PD-L1 antibody product candidate for the treatment of tumors.
The company was founded in 2015 and is based in Foster City, California.
| Country | United States |
| Founded | 2016 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 14 |
| CEO | Hung-Wen Chen |
Contact Details
Address: 989 East Hillsdale Blvd., Suite 220 Foster City, California 94404 United States | |
| Phone | 650 209 4055 |
| Website | apollomicsinc.com |
Stock Details
| Ticker Symbol | APLM |
| Exchange | NASDAQ |
| Share Class | Class A Shares |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 1944885 |
| ISIN Number | KYG0411D1236 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Hung-Wen Chen | Chief Executive Officer and Chairman of the Board |
| K. H. Lin C.A.I.A., M.B.A. | Chief Financial Officer |
| Yi-Kuei Chen | Director and Chief Operating Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 15, 2026 | F-3/A | Filing |
| Apr 27, 2026 | 6-K | Report of foreign issuer |
| Apr 24, 2026 | 20-F | Annual and transition report of foreign private issuers |
| Apr 8, 2026 | SCHEDULE 13D | Filing |
| Apr 6, 2026 | SCHEDULE 13D/A | Filing |
| Apr 1, 2026 | 6-K | Report of foreign issuer |
| Mar 9, 2026 | F-3 | Filing |
| Feb 2, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Dec 22, 2025 | 6-K | Report of foreign issuer |
| Dec 12, 2025 | 6-K | Report of foreign issuer |